GlassScriptPhysician profile
Mukesh N Mehta
NPI 1558361188
$14,659.61
in general payments reported to CMS, 2019-2025
46 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,910 · 2020: $1,642 · 2021: $2,302 · 2022: $1,821 · 2023: $2,102 · 2024: $2,212 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,983.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,267.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,234.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,351.01 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Amgen INC. | $812.89 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $717.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $696.32 | 2021-2025 | |
| Lilly USA, LLC | $538.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $495.19 | 2019-2022 | |
| Pfizer INC. | $473.04 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $451.96 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Astellas Pharma US INC | $427.38 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $424.74 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $410.95 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.11 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $253.29 | 2019-2025 | Eterna, Freestyle Libre 3, Prodigy |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.